Addressing unmet
medical needs

Vaccine development at Valneva
"At Valneva, we take a specialized approach to vaccine development, focusing on disease targets that lack a preventative or therapeutic solution"
Juan Caros Jaramillo MD, Chief Medical Officer
R&D
Investments 2022
€104.9m

Our clinical vaccine pipeline
At Valneva, we take a specialized approach to vaccine development, focusing on disease targets that lack a preventative or therapeutic solution.

Chikungunya – VLA1553
VLA1553 is a single-shot vaccine candidate against chikungunya, a mosquito-borne disease that is highly prevalent in tropical and subtropical regions.

Lyme Disease – VLA15
VLA15 is the only vaccine in advanced clinical development against Lyme disease, the most common tick-borne infection in the northern hemisphere.

Pre-clinical assets
In addition to our clinical portfolio, we are advancing select pre-clinical assets.